XLR-11

XLR-11 (5"-fluoro-UR-144 or 5F-UR-144) is a drug that acts as a potent agonist for the cannabinoid receptors CB1 and CB2 with EC50 values of 98 nM and 83 nM, respectively. It is a 3-(tetramethylcyclopropylmethanoyl)indole derivative related to compounds such as UR-144, A-796,260 and A-834,735, but it is not specifically listed in the patent or scientific literature alongside these other similar compounds, and appears to have not previously been made by Abbott Laboratories, despite falling within the claims of patent WO 2006/069196. XLR-11 was found to produce rapid, short-lived hypothermic effects in rats at doses of 3 mg/kg and 10 mg/kg, suggesting that it is of comparable potency to APICA and STS-135.

Detection
A forensic standard for this compound is available, and a representative mass spectrum has been posted on Forendex.

Recreational use
XLR-11 was instead first identified by laboratories in 2012 as an ingredient in synthetic cannabis smoking blends, and appears to be a novel compound invented specifically for grey-market recreational use.

Legal Status
XLR-11 was banned in New Zealand by being added to the temporary class drug schedule,.

The U.S. Drug Enforcement Administration (DEA) made XLR11 illegal under the Federal Controlled Substances act for the foreseeable future.

It has also been banned in Florida.

Arizona banned XLR-11 on 3 April 2013.

, XLR-11 is a controlled substance in China.

XLR-11 is banned in the Czech Republic.

Side effects
XLR-11 has been linked to hospitalizations due to its use.

Toxicity
XLR-11 has been linked to acute kidney injury in some users, along with AM-2201.